Details for Patent: 8,846,112

Which drugs does patent 8,846,112 protect, and when does it expire?

Patent 8,846,112 protects INOMAX and is included in one NDA.

Protection for INOMAX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has twenty-five patent family members in six countries.

Summary for Patent: 8,846,112

Title:	Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation
Abstract:	Disclosed are methods of distributing a pharmaceutical product comprising nitric oxide gas. The methods include supplying a source of nitric oxide gas to a medical provider, informing the medical provider about a recommended dose of inhaled nitric oxide gas for treatment of neonates with hypoxic respiratory failure, and providing a warning about use of inhaled nitric oxide in patients with pre-existing left ventricular dysfunction.
Inventor(s):	James S. Baldassarre
Assignee:	Mallinckrodt Pharma IP Trading DAC , Therakos Inc , Mallinckrodt Critical Care Finance Inc
Application Number:	US13/683,236
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,846,112
Patent Claim Types: see list of patent claims	Use; Device;

Drugs Protected by US Patent 8,846,112

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-002	Dec 23, 1999		DISCN	Yes	No					Y
Mallinckrodt Ireland	INOMAX	nitric oxide	GAS;INHALATION	020845-003	Dec 23, 1999	AA	RX	Yes	Yes					Y

International Family Members for US Patent 8,846,112

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2009202685
Australia	2010202422
Australia	2010206032
Australia	2012201382